January 26, 2026

Background

Cristina Adriana Popa

POTCAST- K+ Pop and Arrhythmia Drop

This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.

January 11, 2026

Background

Brian Rifkin

A VALIANT effort to combat complement disorders ...

This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.

January 3, 2026

news

Cristina Adriana Popa

Top Stories in Nephrology 2025

2025 was rich in successful stories. Here are the top 10 that impressed our audience.

December 15, 2025

Background

Brian Rifkin

Dialyze Less, Recover More? AKI’s Chance to Get ...

This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

December 1, 2025

Background

Brian Rifkin

Fish Oil in Dialysis: A Big Catch or an Empty ...

Holy Mackerel! This week we will discuss fish oil use in maintenance hemodialysis patients. Could this be the one thing that bends the curve on CV mortality, or is it just a red herring?

liver

swapnil hiremath

April 5, 2021

Commentary

The Trials and Tribulations of Terlipressin

swapnil hiremath

April 5, 2021

Commentary

The Trials and Tribulations of Terlipressin

Elliot Tapper, Director of the Michigan Cirrhosis program and creator of several liver tweetorials, gives us his thoughts on the CONFIRM trial and where we go from here.

swapnil hiremath

April 5, 2021

Background

Terlipressin and Hepatorenal Syndrome: Winning the Battle and Losing the War?

swapnil hiremath

April 5, 2021

Background

Terlipressin and Hepatorenal Syndrome: Winning the Battle and Losing the War?

This week, we will discuss the CONFIRM trial. It was supposed to confirm the role of terlipressin in reversing hepatorenal syndrome…unfortunately it hit the nephrology nihilism wall.